SynthesisAntimicrobial resistance and infection control2020
Risk factors for quinolone-resistant
Synthesis in Antimicrobial resistance and infection control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06305455 (Change in the Resistance Profile of Escherichia Coli in Infections of Community Origin), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Change in the Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- [Antimicrobial resistance characteristics ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Trends in UropathogenicOpen forum infectious diseases · 2025Article
- Antimicrobial susceptibility and genetic profiles of Escherichia coli isolated from poultry hatcheries in the state of Rio Grande do Sul, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Antimicrobial resistance of uropathogens in diabetic patients.BMC infectious diseases · 2025Article
- Mapping socioeconomic factors driving antimicrobial resistance in humans: An umbrella review.One health (Amsterdam, Netherlands) · 2025Review
- Impact of diabetic ketoacidosis on outcomes in hospitalized diabetic patients withProceedings (Baylor University. Medical Center) · 2024Article
- Exposure to Non-Antimicrobial Drugs and Risk of Infection with Antibiotic-Resistant Enterobacteriaceae.Antibiotics (Basel, Switzerland) · 2023Article
- Description of Antimicrobial-ResistantVeterinary sciences · 2023Article
- Fluoroquinolones Are Useful as Directed Treatment for Complicated UTI in a Setting with a High Prevalence of Quinolone-Resistant Microorganisms.Antibiotics (Basel, Switzerland) · 2023Article
- Polyhexamethylene biguanide promotes adaptive cross-resistance to gentamicin inFrontiers in cellular and infection microbiology · 2023Article
- Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay ofAntibiotics (Basel, Switzerland) · 2022Article
- Multidrug-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Infections in Hospitalized Cancer Patients.World journal of oncology · 2021Review
- Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice.Infection and drug resistance · 2021Review
- The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields.Drug target insightsReview
- A Practice Primer and Update on Anti-Bacterial Resistance.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance to quinolone is rising worldwide, especially in Methods: A systematic search was performed to collect published data in the EMBASE, PubMed, and the Cochrane Library up to April 2019. Risk factors were analyzed using the pooled odds ratio (ORs) with 95% confidence interval (CIs). Results: Twenty-seven trials involving 67,019 participants were included in the present study. The following risk factors associated with QREC infection were identified: (1) male (OR = 1.41), (2) hepatic cirrhosis (OR = 2.05), (3) diabetes mellitus (OR = 1.62), (4) cardiovascular disease (OR = 1.76), (5) neurogenic bladder (OR = 8.66), (6) renal dysfunction (OR = 2.47), (7) transplantation (OR = 2.37), (8) urinary tract infection (OR = 2.79) and urinary tract abnormality (OR = 1.85), (9) dementia (OR = 5.83), (10) heart failure (OR = 5.63), (11) neurologic disease (OR = 2.80), (12) immunosuppressive drugs (OR = 2.02), (13) urinary catheter (OR = 4.39), (14) nursing home resident (OR = 4.63), (15) prior surgery (OR = 2.54), (16) quinolones (OR = 7.67), (17) other antibiotics (OR = 2.74), (18) hospitalization (OR = 2.06) and (19) nosocomial infection acquisition (OR = 2.35). Conclusions: QREC infection was associated with nineteen risk factors including prior quinolones use, hospitalization, and several comorbidities. Reducing exposure to these risk factors and modification of antibiotic use are important to prevent quinolone resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.